ID   SW620-FX-R
AC   CVCL_C4RZ
DR   Wikidata; Q116050601
RX   PubMed=36230735;
CC   Population: Caucasian.
CC   Characteristics: Resistant to FOLFOXIRI, the combination of 5-FU, folinic acic, oxaliplatin and SN-38.
CC   Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC   Selected for resistance to: ChEBI; CHEBI:15640; 5-formyltetrahydrofolic acid (Folinic acid; Leucovorin).
CC   Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; L-OHP).
CC   Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0547 ! SW620
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=36230735; DOI=10.3390/cancers14194812;
RA   Ramzy G.M., Boschung L., Koessler T., Delucinge-Vivier C.,
RA   Docquier M., McKee T.A., Rubbia-Brandt L., Nowak-Sliwinska P.;
RT   "FOLFOXIRI resistance induction and characterization in human
RT   colorectal cancer cells.";
RL   Cancers (Basel) 14:4812.1-4812.17(2022).
//